The sale of Warner Bros. Discovery, whether in part to Netflix or as a whole to Paramount, has put cable and broadcast TV in ...
Immuneering Corporation stays a Strong Buy: pancreatic cancer combo shows 64% 12‑mo OS, strong safety, and clear catalysts ...
Company believes that data from sunRIZE and the Expanded Access Program (EAP) provide evidence of activity of ersodetug in ...
KELOWNA, BC / / December 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a ...
Cairo: Drive Finance, a non-banking financial company specialized in consumer finance and a subsidiary of GB Capital, the ...
Clinical study from Baylor College of Medicine demonstrates a favorable safety profile and up to 84.6% disease control rate in patients with pancreatic cancer in Arm A of the clinical study ...
Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets - - Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026 ...
DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus® DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus® Recent financings ...
Wealth quote of the day by SoftBank CEO Masayoshi Son "Life is short. I will regret if I dont act boldly when I am young. The ...
Follow along with these Alabama vs Indiana Odds and Picks to get an expert Rose Bowl Betting guide for the College Football ...
Tennessee will receive more than $1.2 billion in opioid settlement funds. Experts fear the money isn’t reaching people who ...
KELOWNA, BC / ACCESS Newswire / December 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the follo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback